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During vertebrate development, successive phases of embryonic and fetal myogenesis lead to the formation and growth of skeletal muscles 1 . Although the origin and molecular regulation of the earliest embryonic muscle cells is well understood 2 , less is known about later stages of myogenesis. We have identified a new cell population that expresses the transcription factors Pax3 and Pax7 (paired box proteins 3 and 7) but no skeletal-musclespecific markers. These cells are maintained as a proliferating population in embryonic and fetal muscles of the trunk and limbs throughout development. Using a stable green fluorescent protein (GFP) reporter targeted to Pax3, we demonstrate that they constitute resident muscle progenitor cells that subsequently become myogenic and form skeletal muscle. Late in fetal development, these cells adopt a satellite cell position characteristic of progenitor cells in postnatal muscle. In the absence of both Pax3 and Pax7, further muscle development is arrested and only the early embryonic muscle of the myotome forms. Cells failing to express Pax3 or Pax7 die or assume a nonmyogenic fate. We conclude that this resident Pax3/Pax7-dependent progenitor cell population constitutes a source of myogenic cells of prime importance for skeletal muscle formation, a finding also of potential value in the context of cell therapy for muscle disease.
During the onset of skeletal myogenesis in the embryo, Pax3 is required for the survival of the ventro-lateral dermomyotome, the part of the somite that gives rise to hypaxial body 3, 4 and limb 5 musculature. Pax3 is also implicated in the determination of myogenic cell fate, acting through MyoD 6 . In the absence of the myogenic regulatory factors MyoD, Myf5 and Mrf4 (ref. 7) , skeletal muscle does not form and no myogenic cells are present 8 . Most of the functions of Pax3 can be replaced by its paralogue Pax7 (ref. 9 ). However, Pax7, which is also expressed in the somite, is only essential for myogenesis after birth, when it is expressed in satellite cells (the progenitors of adult skeletal muscle) 10, 11 . Pax3 is first expressed in the presomitic mesoderm and this expression is maintained in the somitic epithelium of the dermomyotome [12] [13] [14] [15] (Fig. 1a) . However, at embryonic day (E)10.5, Pax3 is also detected (by immunohistochemistry) in the myotome, the first skeletal muscle to form 16 (Fig. 1b, c) . In less mature posterior somites, this expression is first observed in a few cells lying under the epithelial dermomyotome (Fig. 1a) , whereas in more mature anterior somites, Pax3-expressing cells are found throughout the myotome (Fig. 1b, c) . The number of Pax3-positive (Pax3 þ ) myotomal cells increases as the central dermomyotome loses its epithelial structure (Fig. 1d (middle and right panels) and e), suggesting that they arise directly from the central dermomyotome. Similar results were observed for Pax7, which is first expressed in the central dermomyotome 9, 17 (Supplementary Fig. S1a ) and then co-localizes with Pax3-positive cells in the myotome (Fig. 1e, right 25 At E10.5, expression of the myogenic determination factor Myf5, visualized as b-galactosidase (b-gal) from a Myf5 nlacZ allele, is seen in the lips of the dermomoyotome 16 , which also express high levels of Pax3 (arrows in Fig. 1d ). In contrast, most Pax3 þ Pax7 þ cells in the myotome do not co-express Myf5 (about 93% are Myf5 2 ) ( Fig. 1d and Supplementary Fig S1a) . This lack of co-expresison is also seen for other markers of cell engagement in the myogenic programme, such as desmin ( Supplementary Fig. S1b ) or MyoD (Fig. 1f) . No coexpression was detected for sarcomeric myosin heavy chain (MyHC) (Fig. 1g) , which marks differentiated cells.
The Pax3 þ Pax7 þ population shows labelling with a mitotic marker (Fig. 1h) , indicating the presence of dividing cells. We examined the proliferation of this population compared to the myogenic cells in the myotome, using co-localization with cyclin A, a marker of S and G2 phases (which represent about 50% of the cell cycle length). Data presented in Fig. 1m -o, bottom panels and quantified in Fig. 1p show that about 96% of the Pax3 þ cells in the dermomyotome are dividing, as are 81% of the Pax3 þ Pax7 þ progenitors in the myotome. In contrast, less than 20% of the MyoD þ cells in the myotome are proliferating (Fig. 1o, bottom panel) and only 8% of the Myf5(b-gal) þ cells are proliferating (Fig. 1n , bottom panel), although this lower figure for Myf5 probably reflects b-gal stability from the Myf5 nLacZ allele with labelling of some differentiating muscle cells. Of the total number of cyclinA-positive cells in the myotome, 76% are Pax3 þ (Fig. 1m, lower panel) . We conclude that the Pax3 þ Pax7 þ cells constitute the main proliferating population of the myotome. Cells that are not detected as proliferating might reflect heterogeneity in the cell population, or might correspond to cells that are progressing into the myogenic programme, but for which Pax3 expression is still detectable.
Analysis of skeletal muscle masses at later stages shows that the Pax3 þ Pax7 þ population persists and continues to be distinct from cells that have entered the myogenic programme. MyoD, which marks the myogenic cells, does not co-localize with Pax7, as determined either by staining with an antibody recognizing Pax7 (Fig. 1i,  right panel) or by a more sensitive assay using an antibody to b-gal generated from the Pax7
LacZ allele 18 ( Fig. 1j, right panel) . Similar results were obtained at all stages examined (E11.5-E17. Having identified a novel Pax3 þ Pax7 þ population of proliferating cells distinct from the myogenic cells of skeletal muscle, we then investigated whether this population contributes to the growth of this tissue. We took advantage of the fact that the products of different reporter genes targeted to the Pax3 and Pax7 loci 18 have different stabilities ( Fig. 2s and Supplementary Fig. S2 ). GFP, encoded by the reporter sequence that we targeted to Pax3 (F.R and M.B., unpublished data), is more stable than b-gal generated from the Pax3
IRESnLacZ/þ or Pax7 LacZ/þ alleles 18, 20 , which has comparable stability to the endogenous proteins ( Supplementary Fig. S2 ). Most (93%) of b-gal þ cells detected in trunk muscles of Pax7
LacZ/þ mice at E13.5 or E15.5 do not co-express desmin ( Fig. 2a-d , j-l), but they do co-localize with the GFP þ cells generated from the Pax3 GFP/þ allele ( Fig. 2e) . However, there are additional GFP þ cells that are not Fig. 2e) , and all of these co-localize with desmin at E13.5 ( Fig. 2f) . Similar results were obtained at E15.5, when multinucleated muscle fibres are clearly both GFP-and desmin-positive ( Fig. 2m-o) , in contrast to some individual cells labelled only with GFP (arrows in Fig. 2m-o) . In addition, nearly all (87%) of the Pax7 þ cells are dividing, as shown by co-expression of Ki67, which marks cycling cells ( Fig. 2g-i) , whereas only 9% of the GFP þ /Pax7 2 cells co-express Ki67 (data not shown). At this stage, 89% of cycling cells located within the muscle masses express Pax7, demonstrating that the Pax3 þ /Pax7 þ progenitors constitute the main proliferating cell population ( Fig. 2g-i ). (Fig. 2p-r) . Identical results were obtained with GFP and MyoD ( Supplementary  Fig. S1g-i and data not shown).
We then investigated whether our findings on trunk muscles could be generalized to the limb, where the myogenic cells are derived from a progenitor cell population that migrates from the somites 14, 15 . These cells express Pax3 but not Pax7, which is upregulated at E11 in the mouse embryo 9 . At E13.5, we found that cells expressing Pax7
LacZ/þ are distinct from the desmin-positive muscle cells of the limb ( Supplementary Fig. S1c-f) . Analysis of Pax3 GFP/þ :Pax7
LacZ/þ embryos at this stage also showed that all the Pax7 þ cells express GFP ( Supplementary Fig. S1d-f) and that all the MyoD þ myogenic cells, which do not express Pax7, are marked by GFP ( Supplementary  Fig. S1g-l) . We conclude that the Pax3 þ Pax7 þ cells constitute a novel compartment of resident muscle progenitor cells that contribute to muscle growth during development both in the limbs and trunk.
By E15.5, cells that are Pax3 þ but Myf5(b-gal) 2 are located along, and in close contact with, the muscle fibres (Fig. 2p-r) . Between E16.5 and E18.5 a basal lamina, marked by laminin expression, forms around the muscle fibres, including the associated Pax3 þ Pax7 þ cells (Fig. 3a-o and Supplementary Fig. S1m-o) . This location, under the basal lamina and in close proximity to the muscle fibre, is characteristic of satellite cells, which are the progenitor cells of postnatal skeletal muscle 21 and have been shown to originate from the somite in the chick embryo 22 . In the mouse, these cells express Pax7 (ref. 10) , and in a subset of skeletal muscles also express Pax3 (F.R. and M.B., unpublished data). We found that Pax3 GFP/þ cells become embedded under the basal lamina by E18.5 ( Fig. 3m-o and Supplementary  Fig. S1m-o) and are still detectable during postnatal growth (Fig. 3p-r) . We suggest that the resident muscle progenitor cells present in embryonic and fetal muscle later constitute the satellite cell 
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1 cells contribute to skeletal muscle. a-i, Coimmunohistochemistry at E13.5 on transverse sections from hypaxial trunk muscle of Pax7
LacZ/þ (a-c, g-i) or Pax3 GFP/þ :Pax7 LacZ/þ (d-f) embryos, using antibodies directed against desmin (a, c, d, f), b-gal (b-e, g, i), or Ki67 (h, i). Phase-contrast image shown in a, GFP fluorescence in e, f and DAPI staining in a, b, g. j-r, Co-immunohistochemistry at E15.5 on transverse sections from hypaxial trunk muscle of Pax7
LacZ/þ ( j-l), Pax3 GFP/þ (m-o) or Myf5 nLacZ/þ :Pax3 GFP/þ (p-r) embryos, using antibodies directed against desmin (k-m, o), b-gal ( j, l, q, r) or GFP (n-p, r). Phase-contrast images are shown in j, m, and DAPI staining is shown in j, k, m, n, p, q. population responsible for postnatal muscle growth and regeneration.
As previously reported, Pax7 mutants show no overt muscle defect during development 9, 18 . In contrast, in the trunk, Pax3 mutant embryos display somite truncations 20 with loss of the hypaxial dermomyotome (Fig. 4b,e) , resulting in the reduction and disorganization of hypaxial trunk musculature 3 (Fig. 4h, arrowhead) . The somites of Pax3/Pax7 double mutants are similar to those of Pax3 mutants until E10.5 (Fig. 4b-c) , with initial formation of skeletal muscle in the myotome ( Suplementary Fig. S3a, b) However, as development proceeds, somites become more severely affected and loss of Pax3 þ Pax7 þ cells is observed (Fig. 4f) . Subsequently, most skeletal muscles of the trunk, such as those of the overlying body wall (Fig. 4i) , are severely compromised. By E13.5, only a few muscle fibres are detectable (Fig. 4l) , and at E11.5 there is already a marked deficit of differentiated muscle cells (Fig. 4o) . Pax3 (and Pax7 when substituted for Pax3, ref. 9) assures the survival of early myogenic progenitor cells in the hypaxial dermomyotome 4 . By E11.5, no further apoptosis is observed in the Pax3 mutant, whereas in the Pax3/Pax7 double mutant cell death still occurs (lower panels, Fig. 4m-o) . , l) embryos at E13.5, using DAPI staining and an antibody against MyHC. Loss of skeletal muscle is seen in the double mutant. m-o, Co-immunohistochemistry on transverse sections of thoracic somites of E11.5 embryos as in j-l, using antibodies recognizing MyHC (top panels) and the activated form of caspase 3, which labels apoptotic cells (bottom panels). Endogenous GFP fluorescence is detectable above background and co-localizes with active caspase-3 (arrow in o), indicating that, in contrast to the Pax3 mutant embryos, apoptosis is maintained in the Pax3/Pax7 double mutants at E11.5. p-y, Co-immunohistochemistry (p-s, v-y) and histograms (t, u) using
) or Pax3 GFP/GFP
:Pax7
LacZ/LacZ (Pax3 Cell proliferation, another factor that may affect the capacity of Pax3 þ Pax7 þ progenitor cells to contribute to muscle growth, does not appear to be affected in the GFP þ population in Pax3 GFP/GFP :
Pax7
LacZ/LacZ mutant embryos (Fig. 4p, q) . Notably, GFP-positive cells are still present at E13.5, when there is a marked deficit in skeletal muscle. They are mainly MyoD 2 (Fig. 4r, s, lower panels) , and the remaining MyoD þ cells (3.7% of GFP-expressing cells, compared with 34.6% in the presence of Pax3 and/or Pax7, Fig. 4t ) are all coexpressing terminal differentiation markers (Fig. 4r, s, lower panels,  u) . They probably correspond to differentiated cells dating from the first phase of embryonic myogenesis, when the myotome forms in the absence of Pax3 and Pax7 ( Supplementary Fig. S3 ). This indicates that in the absence of both Pax proteins, myogenic progenitor cells at later embryonic and fetal stages are not specified as skeletal muscle. Instead, they downregulate transcription of the Pax genes, as shown in Fig. 4v , w, lower panels, where b-gal from the Pax7
LacZ allele is no longer detectable (3.2% versus 37.7%) in cells in which the more stable GFP reporter produced from the Pax3 GFP allele (Fig. 4s, Fig. 2s and Supplementary Fig. S2 ) is still present. Identical results to those shown for Pax7
LacZ were obtained with a Pax3
IRESnLacZ allele (data not shown). The GFP-positive mutant cells probably assume non-myogenic fates, as shown by their presence in bones, where they are associated with the expression of markers such as collagen 2a (Col2a, Fig. 4y ), which is characteristic of cartilage cells.
Our results show that after the initial formation of the myotome, which has been a focus in the study of myogenic regulation 2, 16 , subsequent embryonic myogenesis depends on the expression of Pax3 and Pax7, making these factors key upstream regulators of the myogenic process. In the absence of both Pax proteins, resident muscle progenitor cells do not enter the myogenic programme. Double mutants die at mid-gestation, but given the persistence of this cell population and its demonstrated contribution to fetal muscles, we conclude that the skeletal musculature of the fetus also depends on Pax3 and Pax7. The apparent acquisition of satellite cell properties by the Pax3 þ Pax7 þ cells in late fetal muscle suggests that the progenitor cells of postnatal and adult muscle also derive from this population. These cells are compromised in the Pax7 mutant 10 , but some satellite cells are still detectable, suggesting that they are specified correctly 11 ; furthermore, there is no deficit in satellite cells immediately postnatally (F.R., D. Montarras and M.B., unpublished data). This is consistent with a requirement for either Pax3 or Pax7 to generate the cell pool of muscle progenitors from which satellite cells derive. Complementary observations on the origin of the Pax3 þ Pax7 þ population from the dermomyotome of the chick embryo using long-term lineage tracing 23 suggest that the progenitor cells of fetal and postnatal muscle derive from the paraxial mesoderm of the embryonic somite.
The resident muscle progenitor cells that we have identified constitute the principal proliferative cell population of developing skeletal muscle. It is important to determine whether these cells selfrenew as a true stem cell population (see Figs 1m-p and 2g-i). Pax3 and Pax7 have an important role in conferring myogenic potential on these progenitor cells, thus assuring the major phases of skeletal muscle formation as the organism develops. Such cells represent a potentially exploitable resource in the context of cell therapy for muscle diseases.
METHODS
Mice. Generation and genotyping of the Pax3 nLacZ/þ , Pax3 IRESnLacZ/þ and Pax7
LacZ/þ alleles have been previously described 9, 18, 20 . The Pax3 GFP/þ allele will be described elsewere in detail. Briefly, enhanced (E)GFP replaces the Pax3 coding sequence of exon 1, as previously reported for DsRed in the Pax3 DsRed/þ allele 9 . X-Gal staining, histology, immunohistochemistry and in situ hybridization. X-Gal staining, histology, immunohistochemistry and whole-mount in situ hybridization were performed as previously reported 9 . Antibodies used were as follows: MyoD, either a rabbit polyclonal (Santa Cruz; 1:200 dilution) or a
